Company intelligence / Profile preview

Nuformix

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

Nuformix has an early-stage pipeline focused on repurposing approved drugs using novel formulations and delivery methods. Lead asset NXP002 (inhaled tranilast) targets IPF and remains in preclinical development. Other assets are at research or licensing stages. No clinical efficacy data reported yet.

Therapeutic areas: OncologyPulmonology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

NXP004

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

None disclosed as of June 2025; business model focuses on future licensing/partnering at value inflection points

Beyond the preview

Go deeper on Nuformix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuformix.

Explore the full profile